Topic: head and neck cancer
Merck’s Keytruda is duking it out with BMS' Opdivo in head and neck cancer, but Keytruda just took one step toward a big edge.
AstraZeneca is still stinging from Imfinzi’s combo flop in non-small cell lung cancer, but it’s already staring down another defeat.
After batting aside efficacy questions in head and neck cancer, Merck’s Keytruda is back with a new batch of data, this time in new patients.
As a big ESMO 2018 kicks off, here are the studies we're most excited to see.
Merck’s Keytruda may just be on its way to earlier use in head and neck cancer, an area where it once faced some questions.
In April, NICE said it wouldn’t cover BMS’ Opdivo in head and neck cancer due to “uncertain” clinical evidence. Now it's singing a different tune.
In July, Merck’s Keytruda narrowly missed the mark in a head and neck cancer trial. Details of that miss are now here.
The immunotherapy mystery deepens. Merck’s Keytruda missed its goal in a head and neck cancer trial—one its Bristol-Myers rival Opdivo met last year.
Bristol-Myers Squibb’s Opdivo hasn’t even won marketing approval for head and neck cancer in England and Wales yet, but NICE is already shutting it out.
Merck has a plan for boosting its immuno-oncology treatment, Keytruda, in head-and-neck cancer. And it involves patients making plans of their own.